King Pharmaceuticals Completes Review Of Returns ReserveFeb 22, 2005 ...return discussed below, (ii) an impairment of intangible assets and write-off of excess purchase commitments associated with Lorabid(R) (loracarbef), and, as ... - PharmaLive.com (press release),
